BEVERLY, Mass.–(Enterprise WIRE)–Jan 19, 2021–
Cellanyx now announced that Nilesh Patel has been appointed to the Cellanyx board of administrators. Nilesh is a non-public equity govt with an intensive track record in method, functions, analytics and company finance. His experience includes senior positions at Devonshire Traders (the personal fairness arm of Fidelity Investments) and IBM, and most just lately, jogging CFC – a fintech organization.
“Nilesh is an early investor in Cellanyx and shares its eyesight of developing novel cancer exams based on dwell tumor mobile assessment and state-of-the-art AI systems to enhance scientific selection generating,” stated Pravin Chaturvedi, PhD, Cellanyx Govt Chairman. “We seem ahead to his strategic enter as Cellanyx developments its direct take a look at for prostate cancer threat stratification in the direction of commercialization and develops other assessments in its pipeline.”
Prior to CFC, Nilesh was vice president of method & portfolio enhancement at Devonshire Traders – the private fairness arm of Fidelity Investments. At Devonshire, Nilesh drove investment decision method and operational improvement for decide on portfolio providers. He joined Devonshire Investors (then Fidelity Money) in 2006 and has managed multiple acquisition and portfolio initiatives. He also led the advanced analytics group at Devonshire, advising portfolio organizations on facts-driven determination creating and expansion techniques.
Prior to joining Devonshire, Nilesh was Money Strategist at IBM Corporate Headquarters, involved in financial commitment realignments and acquisition/divestiture projects. He has worked at Booz Allen Hamilton on healthcare and pharma manufacturing engagements. Apart from finance/expenditure roles, Nilesh has designed & designed quite a few technology methods, which include engineering software program at Aspen Engineering.
Nilesh obtained a Bachelor of Engineering from Indian Institute of Technologies, Mumbai and an MBA from the Columbia Enterprise School.
Cellanyx is building a proprietary, dwelling mobile phenotypic cancer testing platform to help clinical selection-building. The corporation technological know-how provides quantitative, actionable assessments of person most cancers cells in biopsy samples employing multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic probable. Cellanyx has demonstrated medical proof-of-principle with its direct exam in improvement, a check to boost threat stratification in adult men with prostate cancer. Master much more at www.cellanyx.com.
Keyword: UNITED STATES NORTH The united states MASSACHUSETTS
Industry Search term: BIOTECHNOLOGY Well being ONCOLOGY Medical TRIALS
Copyright Company Wire 2021.
PUB: 01/19/2021 02:45 PM/DISC: 01/19/2021 02:45 PM
Copyright Organization Wire 2021.